Close Menu

NEW YORK (GenomeWeb) – Illumina has pushed back the expected completion date of its acquisition of Pacific Biosciences, due to an ongoing review by UK regulators regarding competition concerns.

Illumina now expects the deal to close in the fourth quarter of 2019, according to a filing with the US Securities and Exchange Commission. The San Diego-based firm also said that the UK Competition and Markets Authority (CMA) announced today that it will refer the proposed acquisition for further review "if the parties are unable to address the CMA's concerns."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

In Nature this week: epigenetic factors that prevent healthy aging and more.

Sponsored by

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.